Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

[1]  Eric A. Meyerowitz,et al.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.

[2]  D. Siegel,et al.  Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study , 2020, The Lancet Rheumatology.

[3]  P. Danaher,et al.  Advances in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene expression data , 2020, bioRxiv.

[4]  A. Iwasaki,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.

[5]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[6]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[7]  M. Addo,et al.  Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease , 2020, Immunity.

[8]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[9]  R. Bartenschlager,et al.  Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells , 2020, Cell reports.

[10]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[11]  J. Alcorn.  IL-22 Plays a Critical Role in Maintaining Epithelial Integrity During Pulmonary Infection , 2020, Frontiers in Immunology.

[12]  M. Fellhauer,et al.  The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation , 2020, Leukemia.

[13]  Andrea Gianatti,et al.  Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study , 2020, The Lancet Infectious Diseases.

[14]  S. Vanni,et al.  Interleukin-6 as prognosticator in patients with COVID-19 , 2020, Journal of Infection.

[15]  Lisa E. Gralinski,et al.  SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.

[16]  B. Lipworth,et al.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[17]  I. Amit,et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 , 2020, Nature Medicine.

[18]  Jie Dong,et al.  Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients , 2020, Cell Host & Microbe.

[19]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[20]  G. Mills,et al.  Multiplex digital spatial profiling of proteins and RNA in fixed tissue , 2020, Nature Biotechnology.

[21]  S. Baldovino,et al.  Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. , 2020 .

[22]  Kwok-Hung Chan,et al.  Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial , 2020, The Lancet.

[23]  Slobodan Paessler,et al.  Antiviral activities of type I interferons to SARS-CoV-2 infection , 2020, Antiviral Research.

[24]  E. Nicastri,et al.  Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.

[25]  T. Kuiken,et al.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.

[26]  Stefano Volpi,et al.  On the Alert for Cytokine Storm: Immunopathology in COVID‐19 , 2020, Arthritis & rheumatology.

[27]  Antonio Bertoletti,et al.  A Dynamic Immune Response Shapes COVID-19 Progression , 2020, Cell Host & Microbe.

[28]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[29]  Fabian J Theis,et al.  SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues , 2020, SSRN Electronic Journal.

[30]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[31]  Zhaohui Zheng,et al.  SARS-CoV-2 invades host cells via a novel route: CD147-spike protein , 2020, bioRxiv.

[32]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[33]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[34]  T. Bestebroer,et al.  Influenza A viruses are transmitted via the air from the nasal respiratory epithelium of ferrets , 2020, Nature Communications.

[35]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[36]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[37]  Kevin J. McHugh,et al.  IL-22 Binding Protein Exacerbates Influenza, Bacterial Super-infection , 2019, Mucosal Immunology.

[38]  Virginia Savova,et al.  Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. , 2019, Immunity.

[39]  Ash A. Alizadeh,et al.  Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.

[40]  Hui Zhao,et al.  Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma , 2016, Oncotarget.

[41]  T. Frankel,et al.  Biological and pathological activities of interleukin-22 , 2016, Journal of Molecular Medicine.

[42]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[43]  J. Renauld,et al.  The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. , 2014, Immunity.

[44]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[45]  David G. Karlin,et al.  Evolution and Structural Organization of the C Proteins of Paramyxovirinae , 2014, PloS one.

[46]  Takanori Nakamura,et al.  Measles Virus Nonstructural C Protein Modulates Viral RNA Polymerase Activity by Interacting with Host Protein SHCBP1 , 2013, Journal of Virology.

[47]  J. Renauld,et al.  Interleukin-22 Is Produced by Invariant Natural Killer T Lymphocytes during Influenza A Virus Infection , 2012, The Journal of Biological Chemistry.

[48]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[49]  K. Sakaguchi,et al.  Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas , 1999, FEBS letters.

[50]  D. H. Park,et al.  Molecular cloning of leukotactin-1: a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. , 1997, Journal of immunology.

[51]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..